Literature DB >> 9872414

BCL-2 promotes migration and invasiveness of human glioma cells.

W Wick1, S Wagner, S Kerkau, J Dichgans, J C Tonn, M Weller.   

Abstract

Malignant progression in gliomas is correlated with increased migratory capacity which involves metalloproteolytic activity. Here, we report that ectopic expression of BCL-2 in two malignant glioma sublines markedly promoted glioma cell migration from spheroids and invasion into Matrigel-coated membranes. Invasion of fetal rat-brain aggregates was enhanced by BCL-2. Zymography revealed activation of matrix metalloproteinase-2 (MMP-2) in BCL-2-expressing cells. BCL-2 expressing cells showed an increase in MMP-2/-3/-12 (LN-18), and MMP-9/-12 and cell surface urokinase-type plasminogen activator (u-PA) (LN-229) mRNA and a reduction in tissue inhibitors of metalloproteinases (TIMP)-2 mRNA (LN-229). Taken together, we propose a novel function for BCL-2 in the malignant phenotype of glioma cells, that is, to enhance migration and invasion by altering the expression of a set of metalloproteinases and their inhibitors.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9872414     DOI: 10.1016/s0014-5793(98)01494-x

Source DB:  PubMed          Journal:  FEBS Lett        ISSN: 0014-5793            Impact factor:   4.124


  27 in total

1.  Decreased level of PDCD4 (programmed cell death 4) protein activated cell proliferation in the lung of A/J mouse.

Authors:  Soon-Kyung Hwang; Arash Minai-Tehrani; Hwang-Tae Lim; Ji-Young Shin; Gil-Hwan An; Kee-Ho Lee; Kee-Rang Park; Yeon-Soo Kim; George R Beck; Hsin-Sheng Yang; Myung-Haing Cho
Journal:  J Aerosol Med Pulm Drug Deliv       Date:  2010-10       Impact factor: 2.849

2.  The tyrosine kinase pyk2 promotes migration and invasion of glioma cells.

Authors:  Christopher A Lipinski; Nhan L Tran; Emmanuel Menashi; Carole Rohl; Jean Kloss; R Curtis Bay; Michael E Berens; Joseph C Loftus
Journal:  Neoplasia       Date:  2005-05       Impact factor: 5.715

Review 3.  Glioma cell invasion: regulation of metalloproteinase activity by TGF-beta.

Authors:  W Wick; M Platten; M Weller
Journal:  J Neurooncol       Date:  2001-06       Impact factor: 4.130

4.  Bcl-2 expression in higher-grade human glioma: a clinical and experimental study.

Authors:  C Fels; C Schäfer; B Hüppe; H Bahn; V Heidecke; C M Kramm; C Lautenschläger; N G Rainov
Journal:  J Neurooncol       Date:  2000-07       Impact factor: 4.130

5.  αB-crystallin is elevated in highly infiltrative apoptosis-resistant glioblastoma cells.

Authors:  Dorota Goplen; Sébastien Bougnaud; Uros Rajcevic; Stig O Bøe; Kai O Skaftnesmo; Juergen Voges; Per Ø Enger; Jian Wang; Berit B Tysnes; Ole D Laerum; Simone Niclou; Rolf Bjerkvig
Journal:  Am J Pathol       Date:  2010-09-02       Impact factor: 4.307

6.  Bcl-2 promotes malignant progression in a PDGF-B-dependent murine model of oligodendroglioma.

Authors:  Tiffany Doucette; Yuhui Yang; Wei Zhang; Gregory N Fuller; Dima Suki; Daniel W Fults; Ganesh Rao
Journal:  Int J Cancer       Date:  2011-03-04       Impact factor: 7.396

7.  Synergistic effects of arsenic trioxide and silibinin on apoptosis and invasion in human glioblastoma U87MG cell line.

Authors:  Majid Zaki Dizaji; Mohsen Malehmir; Ardeshir Ghavamzadeh; Kamran Alimoghaddam; Seyed H Ghaffari
Journal:  Neurochem Res       Date:  2011-10-04       Impact factor: 3.996

8.  Inhibitors of Glioma Growth that Reveal the Tumour to the Immune System.

Authors:  Manuel Nieto-Sampedro; Beatriz Valle-Argos; Diego Gómez-Nicola; Alfonso Fernández-Mayoralas; Manuel Nieto-Díaz
Journal:  Clin Med Insights Oncol       Date:  2011-09-21

Review 9.  Survival signalling and apoptosis resistance in glioblastomas: opportunities for targeted therapeutics.

Authors:  Camilla Krakstad; Martha Chekenya
Journal:  Mol Cancer       Date:  2010-06-01       Impact factor: 27.401

10.  Tumor therapy mediated by lentiviral expression of shBcl-2 and S-TRAIL.

Authors:  Norman Kock; Randa Kasmieh; Ralph Weissleder; Khalid Shah
Journal:  Neoplasia       Date:  2007-05       Impact factor: 5.715

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.